BACKGROUND/AIMS: Several initiatives have started to transfer colorectal cancer follow-up (FU) from secondary to primary care. For this purpose, it is important to assess when and how recurrences of rectal carcinoma are detected after treatment with curative intent. METHODS: Retrospective multicentre cohort study. Patients participating in an FU programme after curative intended treatment for rectal cancer stages I-III between 2007 and 2014. RESULTS: Of the 378 patients, 64 (17%) developed recurrent disease (RD). Most were detected during scheduled FU consultations (n = 55) by (a combination of) radiological examinations and carcinoembryonic antigen levels, and were asymptomatic (n = 53); outside scheduled FU consultations, RD was detected during the treatment of postoperative complications or ostomy reversal (n = 5), or due to symptoms (n = 4). Most frequent sites of recurrence were liver (50%), lung (44%), multiple (22%) or locoregional (16%). Treatment of RD with curative intent was performed more frequently when detected during scheduled FU (60 vs. 22%). The only predictive factor for developing RD was stage III disease on initial presentation. CONCLUSIONS: The majority of rectal cancer patients are diagnosed with RD at an asymptomatic stage during scheduled FU consultations. Only a few patients presented with RD outside the FU programme. Arguably, general practitioners could order these same diagnostic tests during FU.
BACKGROUND/AIMS: Several initiatives have started to transfer colorectal cancer follow-up (FU) from secondary to primary care. For this purpose, it is important to assess when and how recurrences of rectal carcinoma are detected after treatment with curative intent. METHODS: Retrospective multicentre cohort study. Patients participating in an FU programme after curative intended treatment for rectal cancer stages I-III between 2007 and 2014. RESULTS: Of the 378 patients, 64 (17%) developed recurrent disease (RD). Most were detected during scheduled FU consultations (n = 55) by (a combination of) radiological examinations and carcinoembryonic antigen levels, and were asymptomatic (n = 53); outside scheduled FU consultations, RD was detected during the treatment of postoperative complications or ostomy reversal (n = 5), or due to symptoms (n = 4). Most frequent sites of recurrence were liver (50%), lung (44%), multiple (22%) or locoregional (16%). Treatment of RD with curative intent was performed more frequently when detected during scheduled FU (60 vs. 22%). The only predictive factor for developing RD was stage III disease on initial presentation. CONCLUSIONS: The majority of rectal cancerpatients are diagnosed with RD at an asymptomatic stage during scheduled FU consultations. Only a few patients presented with RD outside the FU programme. Arguably, general practitioners could order these same diagnostic tests during FU.
Authors: Peirong Ding; David Liska; Peter Tang; Jinru Shia; Leonard Saltz; Karyn Goodman; Robert J Downey; Garrett M Nash; Larissa K Temple; Philip B Paty; José G Guillem; W Douglas Wong; Martin R Weiser Journal: Ann Surg Date: 2012-07 Impact factor: 12.969
Authors: T Tominaga; T Sakabe; Y Koyama; K Hamano; M Yasutomi; T Takahashi; S Kodaira; T Kato; N Ogawa Journal: Cancer Date: 1996-08-01 Impact factor: 6.860
Authors: Alexander G Heriot; Christopher M Byrne; Peter Lee; Bruce Dobbs; Henry Tilney; Michael J Solomon; John Mackay; Frank Frizelle Journal: Dis Colon Rectum Date: 2008-01-19 Impact factor: 4.585
Authors: Minna Räsänen; Monika Carpelan-Holmström; Harri Mustonen; Laura Renkonen-Sinisalo; Anna Lepistö Journal: Int J Colorectal Dis Date: 2015-03-22 Impact factor: 2.571
Authors: H R Yun; L J Lee; J H Park; Y K Cho; Y B Cho; W Y Lee; H C Kim; H K Chun; S H Yun Journal: Int J Colorectal Dis Date: 2008-08-08 Impact factor: 2.571
Authors: J Wind; L A Duineveld; R P van der Heijden; K M van Asselt; W A Bemelman; H C van Weert Journal: Eur J Surg Oncol Date: 2013-05-18 Impact factor: 4.424
Authors: D A Wattchow; D P Weller; A Esterman; L S Pilotto; K McGorm; Z Hammett; C Platell; C Silagy Journal: Br J Cancer Date: 2006-04-24 Impact factor: 7.640
Authors: John N Primrose; Rafael Perera; Alastair Gray; Peter Rose; Alice Fuller; Andrea Corkhill; Steve George; David Mant Journal: JAMA Date: 2014-01-15 Impact factor: 56.272